Investors are rushing into the relative safe haven of the bond market, causing the yield on the U.S. 10-year Treasury to plummet.Real Estateread more
President Donald Trump on Thursday directed the U.S. intelligence community to "quickly and fully cooperate" with Attorney General William Barr's investigation into the...Politicsread more
Despite a decline in global commercial real estate markets, Asia-Pacific continues to enjoy a record-breaking growth — thanks to China, according to the Global Capital Flows...Real Estateread more
The Wall Street Journal and The New York Times, citing people familiar with the deal, reported that $30 million would go to plaintiffs and $14 million would be used to pay...Entertainmentread more
Wall Street is becoming convinced that both the White House and Beijing are willing to engage in a protracted trade war that could begin to hit consumers and slow global...Market Insiderread more
SpaceX sent 60 satellites into space in a key first mission toward the company's own high-speed internet network.Internetread more
The U.S. Commerce Department said its proposed rule would amend the normal countervailing duty process to include new criteria for currency undervaluation.World Economyread more
Zilingo founder Ankiti Bose says working as an investment analyst helped her build her near-$1 billion fashion start-up.Ditching the Corporate Liferead more
Asia Pacific markets were mostly in negative territory on Friday morning as investors remained worried over trade tensions between the United States and China.Asia Marketsread more
Indian Prime Minister Narendra Modi's Bharatiya Janata Party would have the first back-to-back majority in the lower house of parliament for a single party since 1984.Asia Politicsread more
TransferWise, the money transfer start-up, was valued at $3.5 billion after investors bought $292 million of shares in a secondary sale.Technologyread more
The Senate Finance Committee on Tuesday grilled executives of five of the health care industry's top pharmacy benefit management companies for their alleged role in raising drug costs in the U.S.
Sen. Ron Wyden, D-Ore, the ranking Democrat on the committee, said Tuesday that so-called PBMs are middlemen that strike mysterious deals with drugmakers.
"In my experience, that kind of negotiation rarely results in an act of charity for consumers," Wyden said.
The companies — CVS Health, Cigna, Prime Therapeutics, Humana and OptumRx, a subsidiary of UnitedHealthcare — claimed they do not contribute to skyrocketing prices. Instead, they pointed the blame at drugmakers' high list prices for their products.
PBMs help insurance companies negotiate lower drug costs. Manufacturers arrange discounts, called rebates, with the benefits managers so they can fix a spot for their products on a PBM's list of preferred drugs. That discount is intended to be passed down to the consumer, but lawmakers suspect that the PBMs pocket the money instead.
The benefits managers claimed they do not take the rebates for themselves and that the discounts benefit the consumer as intended.
Sen. Sheldon Whitehouse, D-R.I., asked the executives if they would be willing to increase price transparency by supporting legislation that would permit federal access to drug pricing data. None of the executives opposed, though OptumRx CEO John Prince said he would only support it if the data remained confidential.
The Trump administration has proposed a number of measures to address high drug costs, including plans to eliminate rebates or apply the discount when a consumer purchases their drugs at the pharmacy.
However, limiting rebates or spread pricing (the difference in what PBMs are paid and what they reimburse to pharmacies) may not lower drug costs, according to Patrick Finnegan, senior director at Fitch Ratings.
Finnegan said PBMs use other tactics to earn revenue. Because of that, he's skeptical that limiting rebates or spread pricing will impact drug costs, "especially considering vertical integration trends which increase negotiating power."
Though the executives faced intense scrutiny for their companies' business models, Whitehouse defended the PBMs.
"I stand in awe of the pharmaceutical industry's jiu jitsu magic to have gotten their prime antagonists to become the focus of the problem," Whitehouse said.
Rising drug costs have become a major focus for lawmakers on both sides of the aisle. In February, executives from seven drugmakers testified before the committee, pitching ideas on how to cut prices. The manufacturers blamed the PBM rebates for high consumer costs, while sidestepping any suggestion that they lower their list prices.
Wyden said Tuesday that citizens think "this is all one big scam."
"Every sector of American health care has got to bring more value and lower prices," Wyden said, adding that the industry has to "get beyond the blame game."